Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
S&P Dow Jones Indices is currently seeking public comments from the market regarding potential adjustments to the compilation rules for the S&P U.S. Series Indices and the Dow Jones Total Market Indices concerning mega-cap listed companies.

S&P Dow Jones Indices is currently seeking public comments from the market regarding potential adjustments to the compilation rules for the S&P U.S. Series Indices and the Dow Jones Total Market Indices concerning mega-cap listed companies.

汇通财经汇通财经2026/06/04 22:05
Show original
The inclusion criteria for the S&P 500 Index, S&P MidCap 400 Index, and S&P SmallCap 600 Index will remain unchanged. It is understood that this rule consultation only relates to the index compilation dimensions for mega-cap companies and will not affect the stability of the core admission thresholds of the S&P broad-based index system. Market participants may provide feedback during the consultation period regarding the feasibility and potential impact of the rule amendments for the index company's subsequent evaluation and consideration.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage